Arlington Capital Partners, a Washington, D.C.-based private equity firm, has bought Charles River Laboratories‘ Avian Vaccine Services business to form a new company, AVS Bio.
AVS Bio is a provider of specific pathogen-free (SPF) eggs and adjacent laboratory products and services that support the development and manufacture of vaccines, therapeutics and other biologics used for human and animal health. The company supplies manufacturers with bioprocessing inputs including SPF eggs, antigens and cell products. The company will operate independently as a standalone platform for Arlington that will serve the biologic manufacturing and bioprocessing markets.
“The combination of the Company’s strong market position, deep customer relationships, and unparalleled expertise in SPF products create an ideal foundation on which to build a new bioprocessing platform,” states Mark Giragosian, a vice president at Arlington. “We have tremendous respect for the company’s storied legacy and are excited to invest behind the management team to accelerate its expansion into new markets.”